* ESSA Pharma Inc EPIX.OQ EPIX.O is expected to show no
change
in quarterly revenue when it reports results for the period
ending June 30 2023
*
* LSEG's mean analyst estimate for ESSA Pharma Inc is for a
loss
of 21 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ESSA Pharma
Inc
is $17.00, above its last closing price of $5.49.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2023 -0.19 -0.19 -0.17 Beat 12.8
Mar. 31 2023 -0.20 -0.20 -0.16 Beat 22
Dec. 31 2022 -0.22 -0.23 -0.15 Beat 36.2
Sep. 30 2022 -0.27 -0.14 Beat 49.1
Jun. -0.28 -0.27 -0.20 Beat 25.9
30 2022
Mar. 31 2022 -0.26 -0.25 -0.25 Met 1
Dec. 31 2021 -0.23 -0.23 -0.21 Beat 8.7
Sep. 30 2021 -0.22 -0.23 -0.20 Beat 14
This summary was machine generated December 8 at 12:03 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)